Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive Breast Cancer

Clinical Cancer Research

Volumn 21, Issue 11, 2015, Pages 2487-2498

  Paoletti, Costanza ^a   Muñiz, Maria C ^a   Thomas, Dafydd G ^a   Griffith, Kent A ^b   Kidwell, Kelley M ^b   Tokudome, Nahomi ^a   Brown, Martha E ^a   Aung, Kimberly ^a   Craig Miller, M ^c   Blossom, Dorothy L ^a   Schott, Anne F ^a   Lynn Henry, N ^a   Rae, James M ^a   Connelly, Mark C ^c   Chianese, David A ^c   Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Janssen Pharmaceutical A Johnson and Johnson Co   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; PROTEIN BCL 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CELL LINE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL ASSAY; CELL PROLIFERATION; CIRCULATING TUMOR CELL; CIRCULATING TUMOR CELL ENDOCRINE THERAPY INDEX; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REPRODUCIBILITY; SCORING SYSTEM; VALIDITY; BLOOD; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METASTASIS; PATHOLOGY; PROGNOSIS; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MCF-7 CELLS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 84941954718     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1913     Document Type: Article

References (47)

1. Johnston SRD, Schiavon G. Treatment of metastatic breast cancer: endocrine. In: Harris JR, LippmanM, MorrowM, Osborne CK, editors. Diseases of the breast. 5th ed. Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Tokyo: Wolters Kluwer; 2014. p. 905-28.
2. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984;44:3643-53.
3. Schnipper L. Clinical implications of tumor-cell heterogeneity. N Engl J Med 1986;314:1423-31.
4. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
5. Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP, et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009;29:1557-62.
6. Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 2011;22:2227-33.
7. Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 2012;38:708-14.
8. Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
9. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014 Jun 2. [Epub ahead of print].
10. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 2000;89:111-7.
11. Johnston SR, MacLennan KA, Sacks NP, Salter J, Smith IE, Dowsett M. Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 1994;30A:1663-9.
12. Elledge RM, Green S, Howes L,ClarkGM, Berardo M, Allred DC, et al. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study. J Clin Oncol 1997;15: 1916-22.
13. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-56.
14. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-Talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96:926-35.
15. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992;65: 118-21.
16. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, et al. Shortterm changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005;11:951s-8s.
17. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005;16:1723-39.
18. Yerushalmi R, Woods R, Ravdin PM, HayesMM,Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010;11: 174-83.
19. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-50.
20. Paik S, Shak S, Tang G, Kim C, Baker J, CroninM, et al. A multigene assay to predict recurrence of tamoxifen-Treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
21. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.
22. Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabieres C, Janni W, et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 2013;32:179-88.
23. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904.
24. Fehm T, Muller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: A prospective, multicenter trial. Breast Cancer Res Treat 2010; 124:403-12.
25. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
27. Wolff AC,HammondME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 2014;138:241-56.
28. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101: 1446-52.
29. Ligthart ST, Bidard FC, Decraene C, Bachelot T, Delaloge S, Brain E, et al. Unbiased quantitative assessment ofHer-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. Ann Oncol 2013;24:1231-8.
30. Paoletti C, Smerage J, Hayes DF. Circulating tumor cells as a marker of prognosis. Principles and practice of oncology 2012;26:1-8.
31. Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothe F, et al. International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res 2014;16:R43.
32. Norton L. Implications of kinetic heterogeneity in clinical oncology. Semin Oncol 1985;12:231-49.
33. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2012;2:995-1003.
34. Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 2014;11:129-44.
35. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013; 10:472-84.
36. Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005;90:65-70.
37. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009;20: 1499-504.
38. Edgerton SM, MooreD2nd, Merkel D, Thor AD. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 2003;11: 214-21.
39. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13: 1036-43.
40. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012;30: 587-92.
41. Babayan A, Hannemann J, Spotter J, Muller V, Pantel K, Joosse SA. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS ONE 2013;8:e75038.
42. Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010;16: 2634-45.
43. Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. BreastCancer Res Treat 2009;118:523-30.
44. Lindstrom LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012;30:2601-8.
45. Gee JM, Hutcheson IR. Understanding endocrine resistance: The critical need for sequential samples from clinical breast cancer and novel in vitro models. Breast Cancer Res 2005;7:187-9.
46. Brinkman JA, El-Ashry D. ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J Mammary Gland Biol Neoplasia 2009;14:67-78.
47. Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res 2013;73:1635-46.